Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...
Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...
The Shanghai-based biotech could receive up to $2.7 billion in milestone payments depending on Merck’s progress with the drug across multiple indications. Merck’s Keytruda accounted for $21.6 ...
Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics ... tapped by Merck & Co. in a separate collaboration. 6. Merck KGaA's phase 3 rare tumor trial hits goal, teeing ...
The MANEUVER study met the primary endpoint with an objective response rate (ORR) at week 25 of 54.0% compared with 3.2% <br / ...
The projected annual revenue for Merck is 62,221MM, a decrease of 1.51%. The projected annual non-GAAP EPS is 8.65. What is the Fund Sentiment? There are 5,078 funds or institutions reporting ...
Merck & Co. Inc.’s stock swung between gains ... The Rahway, N.J.-based company posted net income of $3.157 billion, or $1.24 a share, for the quarter, down from $4.745 billion, or $1.86 a ...
Zacks.com on MSN29d
Merck Stock Down More Than 14% in 6 Months: Buy, Sell or Hold?Merck has a Zacks Rank #3 (Hold) stock currently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks ...
Ascentage Pharma (6855.HK) is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in ...
10x Genomics shares tumbled 25% October 10 after reporting preliminary third-quarter revenue of $151.7 million, 1% below Q3 2023 and 6.5% below a ... capital arm of Merck KGaA, Darmstadt, Germany ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback